TY  - JOUR
T1  - POstexposure prophylaxis following hiv exposure
AU  - Kahn JG, Pinkerton SD, Paltiel A
Y1  - 1999/04/14
N1  - 10-1001/pubs.JAMA-ISSN-0098-7484-281-14-jac90002
JO  - JAMA
SP  - 1269
EP  - 1269
VL  - 281
IS  - 14
N2  - 
To the Editor: We believe a critical
issue has been overlooked in the article by Dr Lurie and
colleagues1 and in other discussions of the
cost-effectiveness of PEP after HIV exposure. It is estimated that in
certain circumstances (ie, a sporadic high-risk exposure with a known
seropositive partner), PEP may cost as little as $135,600 per
HIV infection averted—less than the cost of treating HIV
disease.1- 3 Under less favorable circumstances, the cost
may still be less than $50,000 per life-year gained, a figure
that compares favorably with many current uses of patient care
resources.4 For decision makers who aim to maximize total
benefits conferred by health care spending, these results may be cited
to support funding for PEP. We agree with this assessment, provided
that the resources for PEP come from medical care budgets, ie, from
health insurance.

SN  - 0098-7484
M3  - doi: 10-1001/pubs.JAMA-ISSN-0098-7484-281-14-jac90002
UR  - http://dx.doi.org/10-1001/pubs.JAMA-ISSN-0098-7484-281-14-jac90002
ER  -